Infections with extended-spectrum β-lactamase-producing enterobacteriaceae: Changing epidemiology and drug treatment choices

Drugs

Volumn 70, Issue 3, 2010, Pages 313-333

  Pitout, Johann D D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antimicrobial resistance; Bacteraemia; Bacterial infections; Carbapenems; Enterobacteriaceae infections; Fosfomycin; Nitrofurantoin; Temocillin; Therapeutic use; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; BETA LACTAMASE SHV; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; CTX M 15 PROTEIN; ERTAPENEM; ESCHERICHIA COLI PROTEIN; EXTENDED SPECTRUM BETA LACTAMASE; FLOMOXEF; FOSFOMYCIN; GENTAMICIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOCILLIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; DRUG INDICATION; ECONOMIC ASPECT; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; KLEBSIELLA; LABORATORY DIAGNOSIS; MOLECULAR CLONING; MOLECULAR EPIDEMIOLOGY; MORTALITY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; STRAIN DIFFERENCE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HEALTH CARE COSTS; HUMANS; MOLECULAR EPIDEMIOLOGY;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ESCHERICHIA COLI;

EID: 77249104101     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11533040-000000000-00000     Document Type: Review

References (133)

1. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005 Jan 27; 352 (4): 380-391
2. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005 Oct; 18 (4): 657-686
3. Nicolas-Chanoine MH, Jarlier V. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 111-116
4. Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1257-1262
5. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1987-1994
6. Pitout JD, Nordmann P, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005 Jul; 56 (1): 52-59
7. Hawser SP, Bouchillon SK, Hoban DJ, et al. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009 Dec; 34 (6): 585-588
8. Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-produ-cing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009 Aug; 53 (8): 3280-3284
9. Herzer PJ, Inouye S, Inouye M, et al. Phylogenetic dis-tribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. J Bacteriol 1990 Nov; 172 (11): 6175-6181
10. Johnson JR, Delavari P, Kuskowski M, et al. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli. J Infect Dis 2001 Jan 1; 183 (1): 78-88
11. Canton R, Coque TM. The CTX-M beta-lactamase pan-demic. Curr Opin Microbiol 2006 Oct; 9 (5): 466-475
12. Talbot GH, Bradley J, Edwards Jr JE, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006 Mar 1; 42 (5): 657-668 (Pubitemid 43271379)
13. Matsumoto Y, Ikeda F, Kamimura T, et al. Novel plasmid-mediated beta-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother 1988 Aug; 32 (8): 1243-1246
14. Radice M, Power P, Di Conza J, et al. Early dissemination of CTX-M-derived enzymes in South America. Anti-microb Agents Chemother 2002 Feb; 46 (2): 602-604
15. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008 Mar; 8 (3): 159-166
16. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 33-41
17. Poirel L, Lartigue MF, Decousser JW, et al. ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother 2005 Jan; 49 (1): 447-450
18. Poirel L, Naas T, Nordmann P. Genetic support of extended-spectrum beta-lactamases. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 75-81
19. Poirel L, Decousser JW, Nordmann P. Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene. Antimicrob Agents Chemother 2003 Sep; 47 (9): 2938-2945
20. Carattoli A. Resistance plasmid families in Entero-bacteriaceae. Antimicrob Agents Chemother 2009 Jun; 53 (6): 2227-2238
21. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004 Jan; 48 (1): 1-14
22. Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemo-ther 2002 Dec; 50 (6): 1031-1034
23. Laupland KB, Church DL, Vidakovich J, et al. Commu-nity-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008 Dec; 57 (6): 441-448
24. Rodriguez-Bano J, Navarro MD. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 104-110
25. Pitout JD, Church DL, Gregson DB, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007 Apr; 51 (4): 1281-1286
26. Karim A, Poirel L, Nagarajan S, et al. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001 Jul 24; 201 (2): 237-241
27. Novais A, Canton R, Moreira R, et al. Emergence and dissemination of Enterobacteriaceae isolates producing CTX-M-1-like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-host-range (CTX-M-1,-3, and-32) plasmids. Antimicrob Agents Chemother 2007 Feb; 51 (2): 796-799
28. Boyd DA, Tyler S, Christianson S, et al. Complete nu-cleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother 2004 Oct; 48 (10): 3758-3764
29. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoro-quinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006 Jan; 12 (1): 83-88
30. Livermore DM, Canton R, Gniadkowski M,et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007 Feb; 59 (2): 165-174
31. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 159-165
32. Lewis 2nd JS, Herrera M, Wickes B, et al. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007 Nov; 51 (11): 4015-4021
33. Mulvey MR, Bryce E, Boyd D, et al. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1204-1214
34. Villegas MV, Kattan JN, Quinteros MG, et al. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 154-158
35. Zong Z, Partridge SR, Thomas L, et al. Dominance of blaCTX-M within an Australian extended-spectrum beta-lactamase gene pool. Antimicrob Agents Chemother 2008 Nov; 52 (11): 4198-4202
36. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 144-153
37. Ensor VM, Shahid M, Evans JT, et al. Occurrence, pre-valence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006 Dec; 58 (6): 1260-1263
38. Gupta V, Datta P. Extended-spectrum beta-lactamases (ESBL) in community isolates from North India: frequency and predisposing factors. Int J Infect Dis 2007 Jan; 11 (1): 88-89
39. Moubareck C, Daoud Z, Hakime NI, et al. Countrywide spread of community-and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Entero-bacteriaceae inLebanon. J Clin Microbiol 2005 Jul; 43 (7): 3309-3313
40. Blomberg B, Jureen R, Manji KP, et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005 Feb; 43 (2): 745-749
41. Gangoue-Pieboji J, Miriagou V, Vourli S, et al. Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element. Antimicrob Agents Chemother 2005 Jan; 49 (1): 441-443
42. Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, et al. Emergence and outbreaks of CTX-M beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol 2006 Nov; 44 (11): 4049-4056
43. Touati A, Benallaoua S, Djoudi F, et al. Characterization of CTX-M-15-producing Klebsiella pneumoniae and Escherichia coli strains isolated from hospital environments in Algeria. Microb Drug Resist 2007 Summer; 13 (2): 85-89
44. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 134-143
45. Moland ES, Black JA, Hossain A, et al. Discovery of CTX-M-like extended-spectrum beta-lactamases in Escherichia coli isolates from five US States. Antimicrob Agents Chemother 2003 Jul; 47 (7): 2382-2383
46. Castanheira M, Mendes RE, Rhomberg PR, et al. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 2008 Sep; 14 (3): 211-216
47. Pitout JD, Laupland KB, Church DL, et al. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005 Nov; 49 (11): 4667-4670
48. Pallecchi L, Malossi M, Mantella A, et al. Detection of CTX-M-type beta-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother 2004 Dec; 48 (12): 4556-4561
49. Valenzuela de Silva EM, Mantilla Anaya JR, Reguero Reza MT, et al. Detection of CTX-M-1, CTX-M-15, and CTX-M-2 in clinical isolates of Enterobacteriaceae in Bogota, Colombia. J Clin Microbiol 2006 May; 44 (5): 1919-1920
50. Edelstein M, Pimkin M, Palagin I, et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3724-3732
51. Woodford N, Ward ME, Kaufmann ME, et al. Commu-nity and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004 Oct; 54 (4): 735-743
52. Oteo J, Navarro C, Cercenado E, et al. Spread of Escher-ichia coli strains with high-level cefotaxime and ceftazi-dime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006 Jul; 44 (7): 2359-2366
53. Eisner A, Fagan EJ, Feierl G, et al. Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum beta-lactamase in Austria. Antimicrob Agents Chemother 2006 Feb; 50 (2): 785-787
54. Mugnaioli C, Luzzaro F, De Luca F, et al. CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Anti-microb Agents Chemother 2006 Aug; 50 (8): 2700-2706
55. Mendonca N, Leitao J, Manageiro V, et al. Spread of extended-spectrum beta-lactamase CTX-M-producing Escherichia coli clinical isolates in community and noso-comial environments in Portugal. Antimicrob Agents Chemother 2007 Jun; 51 (6): 1946-1955
56. Galas M, Decousser JW, Breton N, et al. Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum- beta-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother 2008 Feb; 52 (2): 786-789
57. Fang H, Ataker F, Hedin G, et al. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008 Feb; 46 (2): 707-712
58. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995 Sep; 33 (9): 2233-2239
59. Lavollay M, Mamlouk K, Frank T, et al. Clonal dis-semination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 2006 Jul; 50 (7): 2433-2438
60. Gonullu N, Aktas Z, Kayacan CB, et al. Dissemination of CTX-M-15 beta-lactamase genes carried on Inc FI and FII plasmids among clinical isolates of Escherichia coli in a university hospital in Istanbul, Turkey. J Clin Microbiol 2008 Mar; 46 (3): 1110-1112
61. Marcade G, Deschamps C, Boyd A, et al. Replicon typing of plasmids in Escherichia coli producing extended-spectrum beta-lactamases. J Antimicrob Chemother 2009 Jan; 63 (1): 67-71
62. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008 Feb; 14 (2): 195-200
63. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25: H4-ST131 producing CTX-M-15. J Antimicrob Chemo-ther 2008 Feb; 61 (2): 273-281
64. Sullivan CB, Diggle MA, Clarke SC. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol Biotechnol 2005 Mar; 29 (3): 245-254
65. Lau SH, Cheesborough J, Kaufmann ME, et al. Rapid identification of uropathogenic Escherichia coli of the O25:H4-ST131 clonal lineage using the DiversiLab repetitive sequence-based PCR system. Clin Microbiol Infect. Epub 2009 Mar 21
66. Pitout JD, Campbell L, Church DL, et al. Using a commer-cial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol 2009 Apr; 47 (4): 1212-1215
67. Clermont O, Dhanji H, Upton M, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemo-ther 2009 Aug; 64 (2): 274-277
68. Johnson JR, Menard M, Johnston B, et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009 Jul; 53 (7): 2733-2739
69. Blanco M, Alonso MP, Nicolas-Chanoine MH, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2009 Jun; 63 (6): 1135-1141
70. Lau SH, Kaufmann ME, Livermore DM, et al. UK epi-demic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother 2008 Dec; 62 (6): 1241-1244
71. Cagnacci S, Gualco L, Debbia E, et al. European emer-gence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008 Aug; 46 (8): 2605-2612
72. Yumuk Z, Afacan G, Nicolas-Chanoine MH, et al. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008 Aug; 62 (2): 284-288
73. Literacka E, Bedenic B, Baraniak A, et al. blaCTX-M genes in Escherichia coli strains from Croatian hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a, blaCTX-M-15) genetic structures. Anti-microb Agents Chemother 2009; 53 (4): 1630-1635
74. Suzuki S, Shibata N, Yamane K, et al. Change in the prev-alence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009 Jan; 63 (1): 72-79
75. Johnson JR, Johnston BD, Jorgensen JH, et al., editors. CTX-M-15-producing E. coli in the United States: predominance of sequence type ST131 (O25:H4). Proceedings of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 2008
76. Naseer U, Haldorsen B, Tofteland S, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009 Jul; 117 (7): 526-536
77. Leflon-Guibout V, Blanco J, Amaqdouf K, et al. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008 Dec; 46 (12): 3900-3905
78. Arpin C, Quentin C, Grobost F, et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobac-teriaceae in the French community setting. J Antimicrob Chemother 2009 Jun; 63 (6): 1205-1214
79. Oteo J, Diestra K, Juan C, et al. Extended-spectrum beta-lactamase- producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents 2009 Aug; 34 (2): 173-176
80. Rooney PJ, O'Leary MC, Loughrey AC, et al. Nursing homes as a reservoir of extended-spectrum {beta}-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009 Sep; 64 (3): 635-641
81. Pomba C, da Fonseca JD, Baptista BC, et al. Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. Antimicrob Agents Chemo-ther 2009 Jan; 53 (1): 327-328
82. Freeman JT, McBride SJ, Heffernan H, et al. Community-onset genitourinary tract infection due to CTX-M-15-producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008 Sep 1; 47 (5): 689-692
83. Pitout JD, Campbell L, Church DL, et al. Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 2009 Jun; 53 (6): 2539-2543
84. Pitout JD, Gregson DB, Campbell L, et al. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009 Jul; 53 (7): 2846-2851
85. Lee SY, Kotapati S, Kuti JL, et al. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006 Nov; 27 (11): 1226-1232
86. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001 Apr 15; 32 (8): 1162-1171
87. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004 Jul 1; 39 (1): 31-37
88. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007 Nov; 60 (5): 913-920
89. Giske CG, Monnet DL, Cars O, et al. Clinical and eco-nomic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008 Mar; 52 (3): 813-821
90. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008 Oct; 6 (5): 751-763
91. Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008; 12 Suppl. 4: S4
92. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 181-184
93. Lopez-Cerero L, Picon E, Morillo C, et al. Comparative as-sessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect. Epub 2009 Jul 15
94. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Entero-bacteriaceae. Antimicrob Agents Chemother 2001 Dec; 45 (12): 3548-3554
95. Pangon B, Bizet C, Bure A, et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 1989 May; 159 (5): 1005-1006
96. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Micro-biol Infect 2000 Sep; 6 (9): 460-463
97. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of Aci-netobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005 Jul; 11 (7): 540-546
98. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 18th informational supplement (CLSI document M100-S18). Wayne (PA): Clinical Laboratory Standards Institute, 2008
99. Szabo D, Silveira F, Hujer AM, et al. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2833-2835
100. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitro-furantoin and tigecycline. Clin Microbiol Infect 2008 Jan; 14 Suppl. 1: 198-202
101. Morosini MI, Garcia-Castillo M, Coque TM, et al. Anti-biotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2695-2699
102. Pitout JD, Le P, Church DL, et al. Antimicrobial suscept-ibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Anti-microb Agents 2008 Oct; 32 (4): 333-338
103. Puerto AS, Fernandez JG, del Castillo D, et al. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006 Feb; 54 (2): 135-139
104. Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004 Jan 15; 38 (2): 243-251
105. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneu-moniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002 Jan 15; 34 (2): 135-146
106. Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemo-ther 2007 Aug; 60 (2): 433-435
107. Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008 Dec; 32 (6): 534-537
108. Skurnik D, Lasocki S, Bremont S, et al. Development of ertapenem resistance in a patient with mediastinitis caused by an extended-spectrum beta-lactamase producing Kleb-siella pneumoniae. J Med Microbiol. Epub 2009 Sep 10
109. Doumith M, Ellington MJ, Livermore DM, et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009 Apr; 63 (4): 659-667
110. Leavitt A, Chmelnitsky I, Colodner R, et al. Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Micro-biol 2009 Apr; 47 (4): 969-974
111. MacGowan AP, Bowker KE, Noel AR. Pharmacody-namics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2008 Apr; 52 (4): 1401-1406
112. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002 Dec; 28 (12): 1718-1723
113. Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006 Dec; 56 (4): 351-357
114. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003 Jan; 21 (1): 1-7
115. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006 Apr 15; 42 Suppl. 4: S164-72
116. ZanettiG,BallyF,GreubG, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemo-ther 2003 Nov; 47 (11): 3442-3447
117. Lee CH, Su LH, Tang YF, et al. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemo-ther 2006 Nov; 58 (5): 1074-1077
118. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006 Feb; 50 (2): 498-504
119. Gavin PJ, Suseno MT, Thomson Jr RB, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2244-2247
120. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006 Dec 1; 43 (11): 1407-1414
121. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Com-munity infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008 Sep 22; 168 (17): 1897-1902
122. Lagace-Wiens PR, Nichol KA, Nicolle LE, et al. Treat-ment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta- lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate. J Antimicrob Chemo-ther 2006 Jun; 57 (6): 1262-1263
123. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002 May; 46 (5): 1481-1491
124. Pitout JD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008 Oct; 6 (5): 657-669
125. de Cueto M, Hernandez JR, Lopez-Cerero L, et al. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 2006 Dec; 24 (10): 613-616
126. Galatti L, Sessa A, Mazzaglia G, et al. Antibiotic prescrib-ing for acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother 2006 Mar; 57 (3): 551-556
127. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemo-ther 2009 Oct; 64 (4): 712-717
128. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharma-codynamic characteristics of tigecycline. Curr Drug Metab 2009 Jan; 10 (1): 13-21
129. Zahar JR, Lortholary O, Martin C, et al. Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 2009 Feb; 10 (2): 172-180
130. Livermore DM, Tulkens PM. Temocillin revived. J Anti-microb Chemother 2009 Feb; 63 (2): 243-245
131. Glupczynski Y, Huang TD, Berhin C, et al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007 Nov; 26 (11): 777-783
132. Barton E, Flanagan P, Hill S. Spinal infection caused by ESBL-producing Klebsiella pneumoniae treated with temocillin. J Infect 2008 Oct; 57 (4): 347-349
133. Nicolle LE, Mulvey MR. Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 2007; 39 (8): 748-749